Comparison
NMN vs CBD (Cannabidiol)
NMN
Nicotinamide mononucleotide — NAD+ precursor. Studied for cellular aging and metabolic health.
CBD (Cannabidiol)
Non-psychoactive cannabinoid from hemp. Anxiolytic, anti-seizure, anti-inflammatory. The supplement market has grown explosively despite mixed evidence base.
| Field | NMN | CBD (Cannabidiol) |
|---|---|---|
| Category | neuroprotective | neuroprotective |
| Dose range | 250–1000mg | 25–600mg |
| Half-life | — | — |
| Onset | — | — |
| Evidence | EVIDENCEB | EVIDENCEB |
| Safety | ●●●●● | ●●●●○ |
| Legal (US) | USOTC | USOTC |
| PubMed refs | 600 | 6800 |
The comparison in plain English
Auto-generated from dataNMN and CBD (Cannabidiol) are both in the neuroprotective category respectively. NMN Nicotinamide mononucleotide — NAD+ precursor. CBD (Cannabidiol) Non-psychoactive cannabinoid from hemp.
Bottom line
NMN (evidence B, safety 5/5) matches the evidence base of CBD (Cannabidiol) (evidence B, safety 4/5). NMN has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose NMN if
NMN is the better fit when your goal aligns with its mechanism (Direct precursor to NAD+ — one biosynthetic step closer than nicotinamide riboside, bypassing the NRK1/NRK2 enzymatic step) and the dose range (250–1000mg) suits your protocol. Half-life is —h.
Choose CBD (Cannabidiol) if
CBD (Cannabidiol) is the better fit when your goal aligns with its mechanism (Modulates the endocannabinoid system through indirect mechanisms — CBD doesn't bind CB1 or CB2 receptors directly like THC does) and the dose range (25–600mg) suits your protocol. Half-life is —h.